RenovoRx, Inc.
RNXT
$0.85
-$0.02-2.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,511.63% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,511.63% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,751.16% | -- | -- | -- | -- |
| SG&A Expenses | 41.38% | 21.04% | 5.98% | 6.27% | -12.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.25% | 24.05% | 15.97% | 11.62% | -3.36% |
| Operating Income | -9.48% | -14.88% | -9.52% | -9.36% | 3.74% |
| Income Before Tax | -26.71% | -21.19% | -31.44% | -26.17% | 13.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.71% | -21.19% | -31.44% | -26.17% | 13.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.71% | -21.19% | -31.44% | -26.17% | 13.86% |
| EBIT | -9.48% | -14.88% | -9.52% | -9.36% | 3.74% |
| EBITDA | -- | -406.09% | -21.63% | 61.76% | -- |
| EPS Basic | 17.95% | 38.76% | 38.94% | 46.19% | 61.93% |
| Normalized Basic EPS | 21.45% | 38.74% | 38.95% | 46.19% | 61.93% |
| EPS Diluted | 17.95% | 38.76% | 38.94% | 46.19% | 61.93% |
| Normalized Diluted EPS | 21.45% | 38.74% | 38.95% | 46.19% | 61.93% |
| Average Basic Shares Outstanding | 58.66% | 73.81% | 95.44% | 124.48% | 116.46% |
| Average Diluted Shares Outstanding | 58.66% | 73.81% | 95.44% | 124.48% | 116.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |